The benzimidazoles are the most broadly used antihelminthic drug class globally, underpinning mass drug administration programs for soil-transmitted helminthiasis that treat hundreds of millions of individuals annually. Their selective toxicity against helminths while sparing mammals rests on a higher binding affinity for helminth beta-tubulin compared with mammalian beta-tubulin, a pharmacodynamic selectivity that has important practical and resistance implications.
Mechanism of Action. Benzimidazoles bind selectively to beta-tubulin in helminth cells, inhibiting its polymerization into microtubules. Microtubules are essential for cell division (mitotic spindle formation), intracellular transport (including glucose uptake via cytoplasmic microtubule-dependent vesicle transport), and maintenance of cell shape. Benzimidazole binding to beta-tubulin at the colchicine-binding site stabilizes the unpolymerized tubulin dimer and prevents microtubule assembly; this disrupts glucose uptake, depletes glycogen stores, and ultimately causes ATP (adenosine triphosphate) depletion and helminth death. The drugs are ovicidal and larvicidal as well as active against adult worms, which is relevant to their role in interrupting transmission. The binding affinity for helminth beta-tubulin is substantially higher than for mammalian beta-tubulin due to differences in the colchicine-binding domain, accounting for the wide therapeutic index in humans at standard oral doses.1
Mebendazole. Mebendazole is minimally absorbed from the gastrointestinal (GI) tract after oral administration, with systemic bioavailability below 10 percent under fasting conditions. This poor absorption is pharmacologically advantageous for intestinal nematode infections, where high luminal drug concentrations are desired without systemic exposure. Mebendazole is the preferred agent for luminal nematode infections including Ascaris lumbricoides (ascariasis), Trichuris trichiura (trichuriasis), Enterobius vermicularis (enterobiasis/pinworm), and hookworm species (Ancylostoma duodenale and Necator americanus). Standard dosing is 100 mg twice daily for 3 days for most intestinal nematodes (except enterobiasis, which requires a single 100 mg dose repeated in 2 weeks to eliminate reinfection from hatching eggs). Because systemic absorption is so limited, mebendazole has essentially no utility for tissue-invasive helminthiasis. It is considered safe in the second and third trimesters of pregnancy for intestinal nematode infections.2
Albendazole. Albendazole is a pro-drug that undergoes first-pass hepatic oxidation to its active sulfoxide metabolite (albendazole sulfoxide, ABZ-SO), which achieves substantially higher systemic plasma concentrations than the parent compound. When taken with a fatty meal, absorption increases 3- to 5-fold, making co-administration with food mandatory for systemic helminthiasis. ABZ-SO distributes widely into tissues including cyst fluid, cerebrospinal fluid (CSF), and bile, making albendazole the benzimidazole of choice for tissue-invasive helminthiasis. The elimination half-life of ABZ-SO is approximately 8 to 12 hours. Albendazole at 400 mg single dose is the WHO (World Health Organization)-recommended treatment for most intestinal nematode infections as part of mass drug administration programs; it is equivalent to mebendazole for luminal nematodes and far superior for tissue-invasive disease.2
Tissue-Invasive Applications of Albendazole. For neurocysticercosis (NCC), caused by larval Taenia solium cysts in the central nervous system (CNS), albendazole 7.5 mg/kg twice daily (maximum 800 mg/day) for 8 to 30 days is the standard antiparasitic treatment, used alongside corticosteroids (dexamethasone or prednisolone) to manage the inflammatory response to dying cysts and antiepileptic drugs for seizure control. The combination of albendazole plus praziquantel for NCC with multiple viable cysts has been shown to achieve greater cyst reduction than either drug alone in several trials. For pulmonary and hepatic echinococcosis (hydatid disease), caused by Echinococcus granulosus, albendazole 400 mg twice daily in 28-day cycles with 14-day rest intervals is used as primary medical therapy (inoperable disease) or as pre- and peri-operative adjunctive treatment to reduce cyst viability and prevent peritoneal seeding. For visceral larva migrans (VLM) caused by Toxocara canis or Toxocara cati, albendazole 400 mg twice daily for 5 days is the preferred treatment.2
Adverse Effects and Contraindications. At the single doses used for intestinal nematode mass drug administration, both mebendazole and albendazole are exceptionally well tolerated, with the most common adverse effects being transient GI disturbance (nausea, abdominal pain) that resolves spontaneously. At the prolonged higher doses used for tissue-invasive helminthiasis, albendazole carries a risk of hepatotoxicity (transaminase elevation in approximately 10 to 17 percent of patients on prolonged therapy, requiring liver function test (LFT) monitoring at 2-week intervals during treatment cycles) and bone marrow suppression (leukopenia, thrombocytopenia), requiring complete blood count (CBC) monitoring. Both benzimidazoles are teratogenic and embryotoxic in animals; they are contraindicated in the first trimester of pregnancy and should be used in the second and third trimesters only when the benefit clearly outweighs risk. The WHO exempts this restriction for single-dose mass drug administration in the second and third trimesters when helminth burden is high and treatment benefit is established.2
Mebendazole: minimal absorption = ideal for luminal nematodes, useless for tissue invasion. Albendazole: fatty meal mandatory for tissue-invasive disease (3–5× absorption increase). Neurocysticercosis: albendazole PLUS corticosteroid (mandatory to manage cyst-death inflammation) PLUS antiepileptic if seizures; consider adding praziquantel for multiple viable cysts. Echinococcosis: albendazole adjunct to PAIR (puncture-aspiration-injection-reaspiration) or surgery; 28-day cycles with 14-day breaks; monitor LFTs every 2 weeks. Both agents teratogenic: contraindicated first trimester; single-dose mass treatment accepted second/third trimester per WHO.2
Ivermectin is a macrocyclic lactone antiparasitic derived from the soil bacterium Streptomyces avermitilis and has become one of the most impactful antiparasitic drugs in history, forming the cornerstone of WHO programs to eliminate onchocerciasis and lymphatic filariasis from endemic regions. Its selective mechanism against invertebrates, wide therapeutic index in mammals, and activity against a broad range of nematodes, ectoparasites, and filarial worms have made it uniquely versatile.
Mechanism of Action. Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels (GluCl channels), which are ligand-gated ion channels present in invertebrate nerve and muscle cells but absent in mammalian central nervous system (CNS) cells (where the blood-brain barrier (BBB) normally prevents ivermectin entry). Ivermectin binding to GluCl channels causes irreversible opening, increasing chloride ion permeability and producing hyperpolarization of invertebrate nerve and muscle cell membranes. This results in flaccid paralysis and death of susceptible organisms. The drug also potentiates gamma-aminobutyric acid (GABA)-gated chloride channels at higher concentrations, contributing to neuromuscular blockade. In mammals, ivermectin does not penetrate the intact BBB under normal circumstances because it is a substrate for the P-glycoprotein (P-gp) efflux pump encoded by the MDR1 (multidrug resistance 1) gene (also called ABCB1). In breeds of dogs and other animals with loss-of-function MDR1 mutations (and in rare humans with significant MDR1 dysfunction), ivermectin can penetrate the CNS and cause neurotoxicity.4
Spectrum: Nematodes. Ivermectin has broad activity against nematodes. Its most important indication is strongyloidiasis, caused by Strongyloides stercoralis, where ivermectin 200 micrograms per kilogram per day for 2 days is the treatment of choice, superior to thiabendazole and albendazole in head-to-head comparisons. In immunocompromised hosts (particularly those receiving corticosteroids), S. stercoralis can cause hyperinfection syndrome (massive autoinfection with filariform larvae crossing the gut wall, carrying enteric bacteria and causing Gram-negative septicemia) and disseminated strongyloidiasis, which carries a mortality exceeding 80 percent if untreated. In immunocompromised patients at risk of hyperinfection, ivermectin is given until two consecutive negative stool examinations are obtained. For enterobiasis (pinworm), ivermectin 200 micrograms per kilogram single dose is an alternative to benzimidazoles. For Ascaris and trichuriasis, ivermectin has limited activity.4
Spectrum: Filarial Infections. Ivermectin is a microfilaricidal agent with selective activity against the microfilariae (larval stage) of filarial nematodes; it is not directly macrofilaricidal (does not reliably kill adult worms) at standard doses, though sustained microfilarial clearance ultimately reduces adult worm reproductive success. For onchocerciasis (river blindness) caused by Onchocerca volvulus, ivermectin 150 micrograms per kilogram annual or semi-annual dosing is the cornerstone of the WHO African Programme for Onchocerciasis Control (APOC), which has dramatically reduced the burden of this blinding disease in endemic communities. For lymphatic filariasis (LF) caused by Wuchereria bancrofti or Brugia malayi, ivermectin combined with albendazole (or diethylcarbamazine (DEC) where onchocerciasis is absent) constitutes the global mass drug administration strategy. A critical safety concern in ivermectin use for filarial infections is the Mazzotti reaction (in onchocerciasis) and severe systemic reactions in patients with high-level Loa loa coinfection (loiasis): in patients with very high L. loa microfilarial densities (above 8,000 microfilariae per milliliter of blood), ivermectin administration can cause fatal encephalopathy from microfilarial death in CNS vessels, requiring careful pre-treatment screening for L. loa in co-endemic regions.5
Spectrum: Ectoparasites. Ivermectin is effective against the ectoparasites Sarcoptes scabiei (scabies) and the lice species Pediculus humanus capitis (head lice), Pediculus humanus corporis (body lice), and Phthirus pubis (pubic lice). For uncomplicated scabies, a single oral dose of ivermectin 200 micrograms per kilogram (repeated in 2 weeks) is an effective alternative to permethrin cream; for crusted (Norwegian) scabies, where a massive mite burden occurs in immunocompromised or elderly patients, ivermectin combined with topical permethrin and repeated dosing is the standard of care because topical therapy alone is insufficient. For head lice with permethrin resistance, oral ivermectin 400 micrograms per kilogram (two doses 7 days apart) provides a non-topical treatment option.4
Pharmacokinetics and Safety. Ivermectin is orally absorbed, with peak plasma concentrations at 4 hours after dosing; absorption is enhanced approximately 2.5-fold by a fatty meal, making co-administration with food recommended. The drug has a large volume of distribution (Vd approximately 46 L/kg), is extensively metabolized by cytochrome P450 3A4 (CYP3A4), and has an elimination half-life of 12 to 16 hours. The major safety concern in humans is potential central nervous system (CNS) toxicity if the BBB is compromised (by meningitis, human immunodeficiency virus (HIV) encephalopathy, or high-dose co-administration of P-gp inhibitors). Standard single oral doses are safe in adults and children above 15 kg. Ivermectin is not routinely recommended in pregnant women or children below 15 kg (below 2 years of age) due to limited safety data in these populations, though its risk-benefit profile may favor use in life-threatening strongyloidiasis hyperinfection during pregnancy.4
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Strongyloidiasis | 200 mcg/kg/day | 2 days | Drug of choice; repeat until stool-negative in immunocompromised |
| Onchocerciasis | 150 mcg/kg | Single dose annually or semi-annually | Screen for Loa loa co-infection; Mazzotti reaction risk |
| Lymphatic filariasis | 200 mcg/kg | Single dose; combined with albendazole | Mass drug administration; Loa loa pre-screening in co-endemic areas |
| Scabies (uncomplicated) | 200 mcg/kg | Single dose; repeat at 2 weeks | Alternative to topical permethrin; especially useful in outbreaks |
| Crusted scabies | 200 mcg/kg | Multiple doses + topical permethrin | Immunocompromised/elderly; topical therapy alone inadequate |
| Head lice (permethrin-resistant) | 400 mcg/kg | 2 doses, 7 days apart | Oral alternative when topical agents fail |
Loa loa co-infection: screen before mass ivermectin administration in Central African regions where L. loa is co-endemic with onchocerciasis. Microfilarial density above 8,000/mL blood = risk of fatal encephalopathy. Strongyloidiasis hyperinfection: associated with corticosteroid use, HTLV-1 infection, and immunosuppression; fatal if missed. Screen all patients from endemic regions (Southeast Asia, sub-Saharan Africa, Central/South America) with unexplained eosinophilia before starting immunosuppressive therapy. BBB compromise: ivermectin toxicity risk increases when P-glycoprotein inhibitors (e.g., ritonavir, verapamil) are co-administered.
Praziquantel is the drug of choice for virtually all trematode (fluke) and cestode (tapeworm) infections in humans, representing one of the most clinically useful drugs in tropical medicine. Its remarkable breadth of activity across phylogenetically distinct parasites united by their tegument structure, combined with favorable pharmacokinetics and an excellent safety profile, has made it essential to WHO programs targeting schistosomiasis, clonorchiasis, opisthorchiasis, taeniasis, and neurocysticercosis.
Mechanism of Action. Praziquantel acts by two complementary mechanisms that operate at clinically relevant concentrations. At low concentrations, it causes increased calcium (Ca²⁺) permeability of the parasite tegument, leading to muscular contraction and spastic paralysis of the worm. At higher concentrations, it causes severe vacuolization and disintegration of the tegument, exposing underlying tegumental antigens that are normally hidden from host immune recognition. Exposure of these cryptic antigens enables host immune effector mechanisms (antibody-dependent cellular cytotoxicity, complement) to attack the worm. The dual mechanism of rapid paralysis plus immune-mediated killing is responsible for praziquantel's lethal efficacy against adult worms. Praziquantel is active against adult forms; it has limited activity against immature flukes (especially young Fasciola hepatica and Schistosoma schistosomula), which may require repeated treatment or alternative agents.6
Pharmacokinetics. Praziquantel is well absorbed orally, with bioavailability of approximately 80 percent that is significantly increased by food (especially carbohydrate-rich meals). It undergoes extensive first-pass hepatic metabolism by cytochrome P450 3A4 (CYP3A4) to inactive hydroxylated metabolites; only a small fraction of unchanged drug reaches systemic circulation, but this fraction is sufficient for efficacy against systemic parasites. Rifampicin, a potent CYP3A4 inducer, dramatically reduces praziquantel plasma levels by up to 85 percent and should not be co-administered; if antituberculosis therapy is required during schistosomiasis treatment, an alternative to rifampicin or praziquantel dose escalation should be considered. Corticosteroids similarly reduce praziquantel concentrations (by approximately 50 percent), which is clinically relevant in neurocysticercosis where both drugs are often co-administered; in this setting, dose adjustment or albendazole (whose cerebrospinal fluid (CSF) penetration is not significantly reduced by corticosteroids) may be preferred.7
Schistosomiasis. Schistosomiasis, caused by Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum (and less commonly S. intercalatum and S. mekongi), affects over 200 million people globally and causes significant morbidity from portal hypertension, bladder disease, and anemia. Praziquantel 40 mg/kg as a single dose (or 20 mg/kg twice in one day for S. japonicum) is the standard treatment for all Schistosoma species. Cure rates exceed 85 percent for most species with a single treatment course; a second course 4 to 6 weeks later substantially improves cure rates and accounts for the maturation of schistosomula that were not susceptible at the time of the first dose. Praziquantel is also used for preventive chemotherapy in mass drug administration programs targeting school-age children in endemic regions.9
Liver Flukes and Other Trematodes. Opisthorchiasis (caused by Opisthorchis viverrini and Opisthorchis felineus) and clonorchiasis (Clonorchis sinensis) are treated with praziquantel 25 mg/kg three times daily for 2 days, achieving cure rates above 90 percent. These liver fluke infections are important because chronic biliary infection with O. viverrini is a recognized carcinogen causing cholangiocarcinoma in Southeast Asia. Fascioliasis (caused by Fasciola hepatica or Fasciola gigantica), in contrast, does not respond to praziquantel because the tegument of Fasciola is inherently resistant; triclabendazole 10 mg/kg as a single dose (or two doses 12 hours apart for severe infection) is the treatment of choice for fascioliasis. Paragonimiasis (lung flukes, primarily Paragonimus westermani) is treated with praziquantel 25 mg/kg three times daily for 2 days.7
Cestodes. Praziquantel is the treatment of choice for intestinal taeniasis caused by Taenia saginata (beef tapeworm) and Taenia solium (pork tapeworm) as a single 5 to 10 mg/kg oral dose, and for Diphyllobothrium latum (fish tapeworm). Niclosamide is an alternative luminal cestocidal agent. For neurocysticercosis (NCC), caused by larval T. solium cysts in the central nervous system (CNS), praziquantel 50 mg/kg/day in three divided doses for 15 to 30 days is an alternative to albendazole; however, as noted above, corticosteroids significantly reduce praziquantel CSF penetration, making albendazole the preferred antiparasitic in the NCC treatment combination. When the combination of albendazole plus praziquantel is used for NCC with multiple viable cysts, praziquantel is added on top of albendazole rather than replacing it, guided by evidence from controlled trials showing superior cyst resolution with the combination.37
Adverse Effects. Praziquantel is generally well tolerated. The most common adverse effects are headache, dizziness, nausea, abdominal pain, and malaise, which are transient and typically attributed to the rapid death of parasites (worm-death reactions) rather than direct drug toxicity. In patients with heavy Schistosoma or T. solium burdens, more pronounced systemic reactions may occur as dying parasites release antigens. In NCC, the antiparasitic-induced inflammatory response around dying cysts can cause seizures, cerebral edema, and, rarely, cerebral herniation; this is why corticosteroids are mandatory concurrently, and why antiparasitic treatment of NCC with calcified-only cysts (which are already dead) provides no benefit and adds only risk. Praziquantel is metabolized extensively in liver disease; caution is warranted in patients with severe hepatic impairment, particularly those with Schistosoma-related portal hypertension.2
Drug of choice for all schistosomes, all intestinal tapeworms, clonorchis, opisthorchis, paragonimiasis. Exception: Fasciola hepatica = use triclabendazole (praziquantel inactive). Rifampicin reduces praziquantel levels 85% — do not co-administer. Corticosteroids reduce praziquantel CSF penetration 50% — use albendazole as primary agent in NCC. NCC treatment: antiparasitic (albendazole +/- praziquantel) + corticosteroid (mandatory) + antiepileptic if seizures; do NOT treat purely calcified NCC (dead cysts; only risk, no benefit). Schistosomiasis: second course 4–6 weeks after first catches maturing schistosomula missed by initial treatment.
Pyrantel pamoate and diethylcarbamazine (DEC) occupy complementary niches in the antihelminthic armamentarium. Pyrantel is a luminal-acting neuromuscular blocker used for common intestinal nematodes, with the advantage of over-the-counter availability in many countries. DEC is the drug of choice for treatment and prophylaxis of lymphatic filariasis and loiasis, and is included in mass drug administration programs for filariasis elimination alongside ivermectin and albendazole.
Pyrantel Pamoate. Pyrantel is a depolarizing neuromuscular blocking agent that acts as a nicotinic acetylcholine receptor (nAChR) agonist in helminth neuromuscular junctions. By producing persistent depolarization and spastic paralysis of the worm, it immobilizes the parasite and allows expulsion by normal intestinal peristalsis. Like mebendazole, pyrantel pamoate is poorly absorbed from the gastrointestinal (GI) tract (less than 15 percent oral bioavailability), confining its activity to the intestinal lumen and making it safe for use in pregnancy (when systemic drug exposure is a concern). It is active against Ascaris lumbricoides, hookworm species, and Enterobius vermicularis but has no activity against Trichuris trichiura, tapeworms, or tissue-invasive helminths. The standard dose is 11 mg/kg (maximum 1 g) as a single oral dose; for enterobiasis, the dose is repeated at 2 weeks to treat newly hatched worms from environmental contamination. Pyrantel and mebendazole act by different mechanisms and are not antagonistic, but there is no established clinical benefit from combining them for intestinal nematodes.8
Adverse Effects of Pyrantel. Pyrantel pamoate is among the safest antihelminthic agents, with adverse effects limited to transient nausea, vomiting, abdominal cramps, and diarrhea occurring in approximately 3 to 10 percent of recipients, particularly those with heavy worm burdens whose intestinal motility changes as worms are expelled. Because pyrantel is a nicotinic acetylcholine receptor (nAChR) agonist, it is theoretically antagonistic to piperazine (which acts by gamma-aminobutyric acid (GABA)-mediated hyperpolarization and flaccid paralysis); the two agents should not be combined. No serious systemic toxicity has been reported at therapeutic doses given the minimal systemic absorption. Pyrantel is available without prescription in most countries and is included in WHO essential medicines lists for childhood deworming programs.2
Diethylcarbamazine. DEC is a piperazine derivative that acts through two mechanisms: it reduces the motility of microfilariae by blocking arachidonic acid metabolite-mediated immune evasion, exposing microfilarial surface antigens to host immune attack, and it may have direct toxic effects on microfilariae at higher concentrations. The drug is predominantly microfilaricidal rather than macrofilaricidal, though repeated courses over years can reduce adult worm survival. DEC is the treatment of choice for lymphatic filariasis when onchocerciasis is not co-endemic (its use in onchocerciasis-endemic areas would cause severe Mazzotti reactions due to dying O. volvulus microfilariae), for loiasis (low microfilarial burden only, due to encephalopathy risk at high Loa loa microfilarial densities), and for tropical pulmonary eosinophilia (TPE), an occult filariasis syndrome caused by immune hyperresponsiveness to microfilariae in the lung. DEC is also used as once-daily prophylaxis for loiasis in expatriates residing in Loa loa-endemic regions in Central Africa.9
Pharmacokinetics and Adverse Effects of DEC. DEC is well absorbed orally, with a bioavailability above 90 percent, a peak plasma concentration at 1 to 2 hours, and an elimination half-life of approximately 8 to 10 hours in individuals with urine pH above 7 (alkaline urine promotes renal reabsorption and extends the half-life; acidic urine promotes ionization and rapid renal excretion). Standard dosing for lymphatic filariasis is 6 mg/kg/day in three divided doses for 12 to 21 days; single-dose 6 mg/kg is used in mass drug administration with albendazole. The most clinically important adverse effects of DEC are not direct drug toxicity but rather parasite-death reactions: fever, headache, arthralgia, urticaria, and lymphangitis (collectively called the Mazzotti-type reaction) reflect immune activation by dying microfilariae. In patients with high Loa loa microfilarial densities (above 8,000 per milliliter of blood), DEC, like ivermectin, can cause severe, potentially fatal encephalopathy from mass microfilarial destruction in central nervous system (CNS) vessels. Pre-treatment assessment of Loa loa burden is therefore mandatory before DEC or ivermectin in co-endemic regions of Central Africa.9
Pyrantel: nAChR agonist causing spastic paralysis; luminal-only activity (Ascaris, hookworm, pinworm); NOT active against Trichuris; safe in pregnancy; do not combine with piperazine (antagonistic mechanisms). DEC: microfilaricidal for lymphatic filariasis and loiasis; drug of choice when onchocerciasis not co-endemic; Loa loa high-burden contraindication (encephalopathy risk); also first-line for tropical pulmonary eosinophilia; DEC prophylaxis for loiasis in high-risk expatriates. In LF mass drug administration: DEC + albendazole where no onchocerciasis; ivermectin + albendazole where onchocerciasis co-endemic.
Drug resistance in helminths is a significant and growing veterinary problem, particularly for benzimidazoles and ivermectin in livestock nematodes, and represents an emerging concern for human medicine as the same drug classes are used for mass drug administration programs. Simultaneously, the clinical management of tissue-invasive helminthiasis, particularly neurocysticercosis and echinococcosis, requires integration of antiparasitic pharmacology with neurosurgical, radiological, and infectious disease expertise.
Benzimidazole Resistance Mechanisms. Resistance to benzimidazoles in helminths is mediated primarily by single-nucleotide polymorphisms (SNPs) in the beta-tubulin gene, particularly at codons 167, 198, and 200 (F167Y [Phe-to-Tyr at 167], E198A [Glu-to-Ala at 198], F200Y [Phe-to-Tyr at 200] using the Haemonchus contortus numbering system). These mutations alter the colchicine-binding site on beta-tubulin, reducing benzimidazole binding affinity without substantially impairing tubulin function. Homozygous codon 200 (F200Y) substitution is the most strongly associated with high-level benzimidazole resistance across multiple helminth species. In veterinary practice, benzimidazole resistance is now present in trichostrongylid nematodes of sheep and cattle on all inhabited continents, raising the concern that the same selection pressure could occur in human populations under sustained mass drug administration with benzimidazoles. Post-treatment cure rate monitoring and molecular surveillance for beta-tubulin SNPs in human soil-transmitted helminthiasis programs are therefore essential components of resistance management.10
Ivermectin Resistance. Ivermectin resistance in veterinary nematodes (primarily Haemonchus contortus in sheep) involves multiple mechanisms including mutations in glutamate-gated chloride channel (GluCl) subunit genes, upregulation of P-glycoprotein drug efflux pumps in the cuticle and intestine, and altered drug transport across the worm cuticle. In human medicine, confirmed clinical ivermectin resistance in Onchocerca volvulus has been reported in foci in West Africa (Ghana, Cameroon, Niger) after many years of annual mass treatment, manifesting as sub-optimal microfilarial suppression despite observed treatment and confirmed drug absorption. The mechanisms appear to involve selection for O. volvulus strains with reduced ivermectin susceptibility rather than complete resistance, but the public health implications for the onchocerciasis elimination program are serious. Enhanced surveillance, alternative treatment regimens, and accelerated development of macrofilaricidal agents (capable of killing adult worms) are active research priorities.1011
Neurocysticercosis: Clinical Management Framework. Neurocysticercosis (NCC), caused by larval T. solium cysts, is the most common cause of acquired epilepsy in low- and middle-income countries. Clinical management is governed by cyst viability and location. Viable cysts (enhancing or non-enhancing parenchymal cysts with scoleces visible on MRI) benefit from antiparasitic therapy; enhancing lesions (representing the immune inflammatory response to dying cysts) also benefit from a short antiparasitic course. Calcified cysts are dead and do not benefit from antiparasitic treatment. Ventricular and subarachnoid (racemose) NCC carry the highest morbidity and require specialized neurosurgical, neuroradiological, and pharmacological co-management. The Infectious Diseases Society of America (IDSA) and American Society of Tropical Medicine and Hygiene (ASTMH) guidelines (2017, updated 2022) recommend albendazole plus praziquantel for multiple viable parenchymal cysts, albendazole alone for single cysts, and the addition of a potent corticosteroid (dexamethasone or prednisolone) in all antiparasitic courses to prevent cyst-inflammation-mediated neurological deterioration.3
Echinococcosis: Medical and Surgical Management. Cystic echinococcosis (CE), caused by Echinococcus granulosus, and alveolar echinococcosis (AE), caused by Echinococcus multilocularis, are both managed with a combination of pharmacological and procedural approaches. For CE, the WHO classification of cyst stages (CE1 through CE5) guides treatment: active cysts (CE1, CE2) are candidates for PAIR (puncture-aspiration-injection-reaspiration with a protoscolicidal agent such as hypertonic saline or cetrimide) or surgical resection with peri-operative albendazole cover; transitional cysts (CE3a, CE3b) may respond to medical therapy or PAIR; inactive cysts (CE4, CE5) may be observed without treatment. Albendazole 400 mg twice daily in 28-day cycles with 14-day rest intervals is given as perioperative prophylaxis (starting at least 4 days before any invasive procedure and continuing for at least 4 weeks after) to reduce the risk of secondary seeding from spillage. For AE, which behaves more like an invasive malignancy than a cyst, radical surgical resection with perioperative and long-term (often lifelong) albendazole is the goal; medically inoperable AE requires indefinite albendazole suppression.12
Beta-tubulin SNP F200Y = primary benzimidazole resistance marker in human helminths; monitor post-treatment cure rates in mass drug administration programs. Ivermectin resistance O. volvulus: emerging in West Africa after sustained mass treatment; detection requires careful parasitological follow-up. NCC management: viable cysts = treat; calcified cysts = do NOT treat (no benefit, seizure risk from inflammation). NCC always requires corticosteroids with antiparasitic treatment. CE: PAIR or surgery + albendazole peri-operative coverage; start albendazole at least 4 days before procedure; continue 4 weeks after. AE: more aggressive than CE; indefinite albendazole for inoperable disease.
Effective antihelminthic prescribing requires identifying the helminth class (nematode, trematode, or cestode), the specific species or syndrome where possible, and the patient context (pregnancy, immunocompromise, co-endemic infections, immigration or travel background) before selecting the agent. The drugs covered in this module collectively address the full spectrum of human helminthiasis, from the common soil-transmitted helminths affecting over a billion people to the rare but life-threatening tissue-invasive syndromes that require combination pharmacological and procedural management.
Drug Selection by Helminth Class. Intestinal nematodes (Ascaris, hookworm, Trichuris) are treated with benzimidazoles (albendazole preferred for programmatic use, mebendazole for single-patient treatment) or pyrantel (for Ascaris and hookworm when benzimidazoles are not available or in pregnancy). Strongyloides stercoralis requires ivermectin as first-line (benzimidazoles have inferior efficacy). Filarial nematodes require ivermectin (microfilaricidal, for onchocerciasis and lymphatic filariasis) or DEC (lymphatic filariasis, loiasis when Loa loa burden is low), with albendazole added for macrofilaricidal augmentation in mass drug administration programs. Trematodes (flukes) are treated with praziquantel, except Fasciola species (triclabendazole). Cestodes (tapeworms, adult intestinal forms) are treated with praziquantel or niclosamide; larval tissue forms (NCC, echinococcosis) require albendazole-based regimens.6
Pregnancy and Antihelminthics. Helminth infections during pregnancy are associated with maternal anemia, intrauterine growth restriction, and low birth weight, making treatment of significant helminth burdens a net benefit in most settings. The WHO recommends single-dose albendazole or mebendazole for soil-transmitted helminthiasis in pregnant women from the second trimester onward in high-prevalence settings. DEC is contraindicated in pregnancy (causes fetal harm in animal studies). Ivermectin use in pregnancy has limited safety data; it is generally avoided except in life-threatening strongyloidiasis hyperinfection where the benefit clearly outweighs risk. Praziquantel is considered safe in pregnancy and is used for schistosomiasis treatment in pregnant women; the WHO includes praziquantel in preventive chemotherapy programs for pregnant women in high-transmission areas.2
Eosinophilia as a Diagnostic and Therapeutic Guide. Peripheral blood eosinophilia (absolute eosinophil count (AEC) above 500 cells per microliter) in a patient with travel to or immigration from a helminth-endemic region should trigger systematic helminth evaluation before initiation of immunosuppressive therapy. Tissue-invasive helminths (Strongyloides, Toxocara, Ascaris larval migration, filarial infection, trichinellosis) cause eosinophilia through interleukin-5 (IL-5)-driven eosinophilopoiesis triggered by helminth-derived antigens. Corticosteroids given to a patient with unrecognized S. stercoralis infection can precipitate hyperinfection syndrome with near-universal fatality; therefore, serological testing for Strongyloides and empirical ivermectin treatment before immunosuppression has been adopted as a standard safety practice in many transplant, rheumatology, and oncology programs. Eosinophilia that resolves after empirical antihelminthic treatment provides indirect evidence of a parasitic cause even when specific organisms are not identified.11
Mass Drug Administration and the Resistance Horizon. WHO preventive chemotherapy programs deliver benzimidazoles, ivermectin, praziquantel, and DEC to hundreds of millions of individuals annually in endemic countries, representing one of the largest pharmacological interventions in public health history. The sustainability of these programs depends entirely on maintaining drug efficacy. Current evidence supports continued efficacy of all four drug classes in human infections, with the most concerning signals from ivermectin in onchocerciasis in localized West African foci.11 Monitoring platforms including the WHO-GAELF (Global Alliance to Eliminate Lymphatic Filariasis), the African Programme for Onchocerciasis Control (APOC) successor program (ESPEN [Expanded Special Project for Elimination of Neglected Tropical Diseases]), and academic consortia provide ongoing surveillance. Clinicians treating patients from endemic regions should report unexpected treatment failures to national public health authorities to support this surveillance infrastructure.1011
Intestinal nematodes: albendazole 400 mg single dose (preferred) or mebendazole. Strongyloides: ivermectin 200 mcg/kg/day ×2 days (not benzimidazoles). Onchocerciasis: ivermectin annual or semi-annual; screen for Loa loa co-infection. Lymphatic filariasis MDA: DEC + albendazole (no onchocerciasis) or ivermectin + albendazole (onchocerciasis co-endemic). Schistosomiasis: praziquantel 40 mg/kg single dose; second course at 4–6 weeks. Fasciola: triclabendazole (NOT praziquantel). NCC: albendazole + corticosteroid mandatory; add praziquantel for multiple viable cysts; never treat calcified-only NCC. Echinococcosis: albendazole + PAIR or surgery; start 4 days pre-procedure. Eosinophilia + immunosuppression: test and treat Strongyloides before starting steroids or other immunosuppressants.
Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol. 1988;18(7):885-936.
doi:10.1016/0020-7519(88)90175-XBrunton L, Knollmann B, Hilal-Dandan R, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill; 2023. Chapter 51: Chemotherapy of Helminth Infections.
doi:10.1036/9781264258987White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66(8):e49-e75.
doi:10.1093/cid/cix1084Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother. 1994;34(2):195-203.
doi:10.1093/jac/34.2.195Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv Parasitol. 2006;61:349-394.
doi:10.1016/S0065-308X(05)61009-3Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34(4):527-533.
doi:10.1016/j.ijpara.2003.12.003Garcia HH, Evans CAW, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15(4):747-756.
doi:10.1128/CMR.15.4.747-756.2002Aubry ML, Cowell P, Davey MJ, Shevde S. Aspects of the pharmacology of a new anthelmintic: pyrantel. Br J Pharmacol. 1970;38(2):332-344.
doi:10.1111/j.1476-5381.1970.tb08523.xGyapong JO, Gyapong M, Yellu N, et al. Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. Lancet. 2010;375(9709):160-165.
doi:10.1016/S0140-6736(09)61249-9Prichard RK, Basanez MG, Boatin BA, et al. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis. 2012;6(4):e1549.
doi:10.1371/journal.pntd.0001549Churcher TS, Pion SD, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci USA. 2009;106(39):16716-16721.
doi:10.1073/pnas.0906176106Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16.
doi:10.1016/j.actatropica.2009.11.001